In Vitro Assessment of the Genotoxic Hazard of Novel Hydroxamic Acid- and Benzamide-Type Histone Deacetylase Inhibitors (HDACi)

Histone deacetylase inhibitors (HDACi) are already approved for the therapy of leukemias. Since they are also emerging candidate compounds for the treatment of non-malignant diseases, HDACi with a wide therapeutic window and low hazard potential are desirable. Here, we investigated a panel of 12 nov...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedrich, Annabelle, Assmann, Ann-Sophie, Schumacher, Lena, Stuijvenberg, Jana v., Kassack, Matthias U., Schulz, Wolfgang A., Roos, Wynand P., Hansen, Finn K., Pflieger, Marc, Kurz, Thomas, Fritz, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370100/
https://www.ncbi.nlm.nih.gov/pubmed/32635356
http://dx.doi.org/10.3390/ijms21134747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370100/
https://www.ncbi.nlm.nih.gov/pubmed/32635356
http://dx.doi.org/10.3390/ijms21134747

Ejemplares similares